- Home
- CASY vs BIIB Comparison
CASY vs BIIB Comparison
Compare CASY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASY
- BIIB
- Stock Information
- Founded
- CASY 1959
- BIIB 1978
- Country
- CASY United States
- BIIB United States
- Employees
- CASY N/A
- BIIB N/A
- Industry
- CASY Diversified Commercial Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CASY Miscellaneous
- BIIB Health Care
- Exchange
- CASY Nasdaq
- BIIB Nasdaq
- Market Cap
- CASY 19.5B
- BIIB 18.7B
- IPO Year
- CASY N/A
- BIIB 1991
- Fundamental
- Price
- CASY $518.50
- BIIB $141.04
- Analyst Decision
- CASY Buy
- BIIB Buy
- Analyst Count
- CASY 12
- BIIB 27
- Target Price
- CASY $467.33
- BIIB $188.09
- AVG Volume (30 Days)
- CASY 272.2K
- BIIB 1.4M
- Earning Date
- CASY 09-08-2025
- BIIB 10-29-2025
- Dividend Yield
- CASY 0.45%
- BIIB N/A
- EPS Growth
- CASY 9.01
- BIIB 31.67
- EPS
- CASY 14.64
- BIIB 10.45
- Revenue
- CASY $15,940,899,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- CASY $11.07
- BIIB $2.00
- Revenue Next Year
- CASY $5.73
- BIIB N/A
- P/E Ratio
- CASY $35.62
- BIIB $13.52
- Revenue Growth
- CASY 7.25
- BIIB 3.36
- 52 Week Low
- CASY $362.42
- BIIB $110.04
- 52 Week High
- CASY $531.24
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- CASY 60.78
- BIIB 60.59
- Support Level
- CASY $505.00
- BIIB $137.14
- Resistance Level
- CASY $505.65
- BIIB $144.20
- Average True Range (ATR)
- CASY 8.63
- BIIB 3.89
- MACD
- CASY 1.10
- BIIB 0.32
- Stochastic Oscillator
- CASY 98.59
- BIIB 70.33
About CASY Casey's General Stores Inc.
Casey's General Stores Inc serves as convenience store chain with its 2,900 locations, positioned in the Midwest United States. About half of Casey's stores are located in rural towns with populations under 5,000. While fueling stations serve as a key traffic driver, about two-thirds of the company's gross profit stems from in-store sales of grocery items, prepared meals, and general merchandise. Casey's owns more than 90% of its stores and operates the majority of its warehousing and distribution processes internally.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.